Highlights

  • Island Pharmaceuticals (ASX:ILA) rose 8.70% to AUD 0.50 and is up about 122% over one year.
  • The Phase 2a PROTECT dengue program with ISLA-101 has been completed.
  • Galidesivir adds Ebola and Marburg exposure to the pipeline.
  • The company received regulatory and operational milestones across both programs during 2026.

Island Pharmaceuticals Limited (ASX:ILA) rose 8.70% to AUD 0.50, extending its one-year gain to about 122%. Turnover reached roughly AUD 253,000 and the company is valued near AUD 148mn. The rerating has developed alongside a broader infectious-disease pipeline that now combines the dengue-focused ISLA-101 program with galidesivir for severe viral diseases including Ebola and Marburg.

ISLA-101 remains the dengue program

The PROTECT Phase 2a program has been completed and is intended to provide clinical information around both prophylactic and treatment use. The company has also continued expanding intellectual-property protection around the asset.

Galidesivir adds a second clinical pathway

Island has advanced galidesivir through regulatory work aimed at diseases such as Ebola and Marburg. The FDA has provided feedback around an Animal Rule pathway, and the asset has received orphan-drug designation for Marburg.

A two-program model changes the risk profile

The company is no longer dependent on one infectious-disease asset. Dengue and filovirus programs address different markets and regulatory pathways, reducing single-asset concentration but increasing development complexity.

The growth case

Successful regulatory progression could create access to large public-health markets where approved treatments remain limited. Priority Review Voucher eligibility can also add strategic value if an approval is eventually achieved.

The risks

Clinical outcomes remain uncertain, and infectious-disease development can depend on trial access, outbreaks and regulatory design. Both programs require continued funding before commercial revenue.

What to watch next

PROTECT data interpretation, galidesivir regulatory milestones, trial design, cash runway and potential government or commercial partnerships are the main indicators.